Decreased expression of Annexin A10 in gastric cancer and its overexpression in tumor cell growth suppression

JEONG KYU KIM1*, PUM JOON KIM2*, KWANG HWA JUNG1, JJ HEON NOH1, JUNG WOO EUN1, HYUN JIN BAE1, HONG JIAN XIE1, JIN MEI SHAN3, WANG YING PING3, WON SANG PARK1, JUNG YOUNG LEE1 and SUK WOO NAM1

1Department of Pathology, Microdissection Genomics Research Center; 2Department of Cardiology, College of Medicine, The Catholic University of Korea, Seoul, Korea; 3Department of Pathology, First Hospital Jilin University, Changchun, P.R. China

Received March 26, 2010; Accepted June 2, 2010

DOI: 10.3892/or_00000898

Abstract. Gastric carcinoma is the most common neoplasm in Southeast Asian populations and is the second leading cause of cancer death worldwide. Annexins are a family of cytosolic calcium and membrane binding proteins that have been implicated in a wide variety of cell functions. Recent studies have suggested that Annexin A10 (ANXA10), a member of the Annexin protein family, is down-regulated in specific types of cancer. However, the underlying molecular mechanisms of the dysregulation of ANXA10 remain to be elucidated. In the present study, to investigate the biological effects of ANXA10 on gastric carcinoma, aberrant expression of ANXA10 was evaluated by Western blot analysis, reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC), in gastric cancer tissues and cell lines. Decreased expression of ANXA10 was observed in five selected gastric cancer tissues compared to the normal surrounding mucosa. In the cancer cell lines, seven out of nine selected gastric cancer cell lines had no detectable ANXA10 by RT-PCR. Among these, when an ANXA10 expressing plasmid was introduced into MKN-1 cells, cell growth was suppressed and apoptosis augmented. The results of this study demonstrated that ANXA10 was aberrantly regulated in gastric carcinoma and suggests that down-regulation of ANXA10 might be involved in gastric carcinogenesis. In addition, ANXA10 may play a role, as a tumor suppressor, in the development and progression of gastric cancer.

Introduction

Gastric cancer is the most common malignancy in Korea and some of the other Southeast Asian populations; it is the second leading cause of cancer death worldwide (1). However, the mechanism associated with the development of gastric cancer and progression has not been determined. Carcinogenesis is a multi-step process that is associated with alterations of cellular oncogenes and tumor suppressor genes necessary for malignant transformation (2-4). In gastric carcinogenesis, it has also been suggested that multiple genetic alterations are responsible for the development and progression of gastric cancer, and alterations in specific genes that play an important role in diverse cell activity such as cell adhesion, signal transduction, differentiation, development and DNA-repair; genes for such functions have been identified (5-8). However, many of these putative oncogenes or tumor suppressor genes require further study as future targets for therapeutic interventions in patients with gastric cancer. Recent studies have confirmed chromosomal alterations in gastric cancer. The loss of many chromosomal loci such as: 1p, 2p, 3p, 4p, 5q, 6q, 7q, 8q, 12q, 13p, 14q, 17p, 17q and 18q have been found in gastric cancers (9-13). However, the mechanisms of loss, of these loci and certain genes, are poorly understood. Furthermore, it is unclear how these genetic changes correspond to the clinical characteristics of individual patients with gastric cancer. Therefore, improvements in diagnostic, protective and treatment strategies require a better understanding of the various mechanisms underlying gastric carcinogenesis.

Annexins (ANXs) are a family of cytosolic calcium-regulated proteins and membrane-binding proteins that have been implicated in diverse biological processes that link ANX to many membrane-related events, such as the regulated organization of membrane domains and/or membrane-cytoskeleton links, certain exocytic and endocytic transport steps and the regulation of ion fluxes across membranes (14). The activity of these proteins are mediated by Ca2+ dependent signal transduction pathways also involved in the regulation of the cell cycle, growth, vesicle trafficking, and apoptosis (14-19). Moreover, recent studies have shown that ANXs are
implicated in complex mechanisms, and abnormal expression of ANX protein levels have been correlated with tumor progression. In various cancers, certain ANXs are thought to participate in carcinogenesis. Expression of ANXA1, 2, 7, 8 and 11 has been reported to be up- or down-regulated, ANXA3, 4 and 6 to be up-regulated and ANXA10 to be down-regulated in specific types of cancer (20). The down-regulation of the ANXA10 protein, was first identified in higher vertebrates, and has been correlated with the presence of a p53 mutation and poor prognosis in patients with hepatocellular carcinoma (21). Recently, ANXA10 expression was found to be reduced in mucinous adenocarcinoma, and low ANXA10 expression was also found to be associated with a poor prognosis (13). These results suggest that ANXA10, at least in part, participates in the process of tumor progression.

In the present study, to investigate the biological role of ANXA10 in gastric carcinogenesis, expression of ANXA10 in gastric cancer was compared to corresponding normal stomach tissues and was also confirmed in gastric carcinoma cell lines. In addition, to explore the biological role of ANXA10 in gastric cancer, a recombinant ANXA10 was constructed and in vitro tumor growth and apoptosis assays performed.

Materials and methods

**Tissue samples and tissue microarray.** Five frozen human gastric cancers and their corresponding normal tissues were obtained from Jilin University; the samples were randomly selected for this study. Approval was obtained from the institutional review board of the Jilin University of China. Informed consent was provided according to the Declaration of Helsinki. For the tissue microarray (TMA), the intestinal-type was present in 40 cases, 62 were the diffuse-type and 20 were the mixed-type of gastric cancer. The mean tumor size was 6.37 cm and 122 tumors were located in the middle or lower section of the stomach. For the TMA construction, a total of 122 gastric cancer specimens from formalin fixed, paraffin-embedded gastric cancer samples were obtained from the archives of the Department of Pathology at our institution. Two pathologists screened the histological sections and selected areas representative of the tumor cells. Two and one tissue core samples, from each cancer and normal tissue, were taken and placed in a new recipient paraffin block using a commercially available microarray instrument (Beecher Instruments, Micro-Array Technologies, Silver Spring, MD, USA), according to established methods (22). Approval was obtained from the institutional review board of the Catholic University of Korea, College of Medicine. There was no evidence of familial cancer in any of the patients.

**Cell culture and reagents.** MKN-1, MKN-28, MKN-74, SNU-216, SNU-484, SNU-638, SNU-668 and SNU-719 cells were purchased from the Korean Cell Line Bank (KCLB, Seoul, Korea) and AGS cells were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Each cell line was grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO, USA). MKN-1 cells were trypanosed, and then seeded at 2x10^5 cells/plate in a 60-mm dish, and allowed to grow overnight at 37°C in a humidified incubator with 5% CO₂. At 24 h after plating, the cells were transfected with ANXA10-specific siRNAs in Opti-MEM (Life Technologies, Gaithersburg, MD, USA). Transfection was carried out using oligofectamine reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's specifications.

**Reverse transcriptase-polymerase chain reaction (RT-PCR).** The total RNA from the MKN-1 cells was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The RNA concentration was determined by NanoDrop (Thermo Fisher Scientific Inc., Waltham, MA, USA). Next, 1 μg of total RNA was reverse transcribed using the Superscript II enzyme (Gibco-BRL, Gaithersburg, MD, USA) with 2.5 μM oligo (d)T (Amersham Biosciences, Piscataway, NJ, USA). The reaction mixture was incubated at 42°C for 60 min and then at 72°C for 15 min. To normalize differences in the amount of total cDNA added to each reaction, glyceraldehydes-3-phosphate dehydrogenase (GAPDH) gene expression was used as an endogenous control. The cycling conditions were: initial denaturation at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec, 58°C for 5 sec, 72°C for 5 sec. ANXA10 and GAPDH transcripts were measured using agarose gel electrophoresis.

**Western blot analysis.** The following antibodies were used: anti-ANXA10, -GAPDH, -α-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-PARP (Cell Signaling Technology, Danvers, MA, USA), anti-mouse IgG (Amersham Biosciences), anti-rabbit IgG (Bio-Rad Laboratories, Hercules, CA, USA) and the ECL plus Western blotting detection kit I (BD Biosciences, San Jose, CA, USA) with 2.5 μM oligo (d)T (Amersham Biosciences, Piscataway, NJ, USA). The RNA concentration was determined by NanoDrop (Thermo Fisher Scientific Inc., Waltham, MA, USA) with 2.5 μM oligo (d)T (Amersham Biosciences, Piscataway, NJ, USA). The reaction mixture was incubated at 42°C for 60 min and then at 72°C for 15 min. To normalize differences in the amount of total cDNA added to each reaction, glyceraldehydes-3-phosphate dehydrogenase (GAPDH) gene expression was used as an endogenous control. The cycling conditions were: initial denaturation at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec, 58°C for 5 sec, 72°C for 5 sec. ANXA10 and GAPDH transcripts were measured using agarose gel electrophoresis.

**Cell counts for cell growth.** The effect on cell growth was determined by counting cells at the indicated time with the use of a hemocytometer. Briefly, the MKN-1 cells were seeded in 12-well flat-bottomed microtiter plates at a density of 2x10^4 cells per well. The cells were transfected with recombinant plasmid containing ANXA10 or a Mock vector, and then the cells were allowed to grow for the indicated time. The cells were trypsinized and then counted using staining with trypan blue (0.8% in PBS). All measurements were performed in triplicate and each experiment was repeated at least 3 times.

**Apoptosis analysis.** The Annexin V-FITC Apoptosis Detection kit I (BD Biosciences, San Jose, CA, USA) was used to
quantify the level of apoptosis in the samples. Briefly, after transfection, the cells were trypsinized, washed twice with cold PBS and resuspended in 1X binding buffer at a concentration of 1x10^6 cells/ml, and 100 μl of the solution (1x10^5 cells) was transferred to a 5 ml culture tube and 5 μl of Annexin V-FITC solution was added; 10 μl of PI was added to each tube and the cells were analyzed by flow cytometry.

**Statistical analysis.** Each experiment was performed at least three times. The data are presented as the mean ± standard errors for the number of experiments. Statistical significance was defined by the results of the unpaired Student’s t-test at a P<0.05 and the Chi-square test for immunohistochemistry.

**Results**

**Decreased expression of ANXA10 in gastric cancers.** ANXA10 is located on chromosome 4 at the q33 band (26); chromosome 4q is one of the most common regions with a high frequency of allelic loss in HCC. Recent studies have shown that reduced expression of ANXA10 is associated with gastric carcinoma. However, its role in gastric carcinoma has not been clearly defined. Thus, in order to investigate the aberrant expression of ANXA10 in gastric carcinoma, the expression levels of ANXA10 in both gastric cancer cell lines and human gastric cancer tissues were measured and compared. In the gastric cancer cell lines, when the expression of ANXA10 by RT-PCR and Western blot analysis was assessed, most of the cancer cell lines derived from gastric carcinoma showed a reduced expression of ANXA10.

In the gastric cancer cells, ANXA10 was not detectable by both RT-PCR and Western blot analysis; with the exception of the SNU-620 and SNU-719 cell lines (Fig. 1B). In order to confirm the aberrant expression of ANXA10 in gastric carcinoma, the differential expression of ANXA10 was determined in five selected human gastric carcinoma tissues. As shown in Fig. 1A, expression of the ANXA10 protein level was found to be reduced in the tumor tissues compared to the corresponding normal tissues. The protein expression of ANXA10 was further validated by immunostaining of the gastric cancer specimens with ANXA10 antibodies; the results are summarized in Fig. 2 and Table I. Briefly, 31 out of the 122 gastric carcinomas tested (25.4%) had negative or weak positive staining with the ANXA10 antibodies, while 102 out of the 122 (83.6%) normal gastric tissues showed moderate or strong expression of ANXA10 in the normal adjacent tissues. Fig. 2 shows a representative image of normal and gastric carcinoma tissues (Fig. 2A), magnified...
normal gastric tissues (Fig. 2B) and gastric cancer tissues (Fig. 2C).

Overexpression of ANXA10 inhibits cell growth and induces apoptosis of MKN-1 cells. To determine the biological consequences of dysregulation of ANXA10 expression, whether ANXA10 was a suppressor of growth in a gastric cancer cell line was evaluated. MKN-1 cells, which did not express ANXA10, were transiently transfected with a control plasmid (pcDNA3.1/HisC) or with an ANXA10 plasmid (pcDNA3.1/HisC_ANXA10-clone1, -clone3). As shown in Fig. 3A, introducing an ANXA10 expression vector into the MKN-1 cells was associated with effective expression of ANXA10 in the MKN-1 cells compared to the non-expressing (Mock) vector. To determine the biological effects of overexpression of ANXA10, the growth rate of the MKN-1 cells was determined using the cell counting assay. As shown in Fig. 3B, overexpression of ANXA10 significantly reduced cell growth compared to cells treated with the pcDNA3.1/HisC_Mock vector. The anti-mitogenic effects on the MKN-1 cells could be partially explained by the augmentation of cellular senescence or apoptosis. Indeed, cleavage of poly-ADP-ribose polymerase (PARP) was observed when ANXA10 was transfected, a hallmark of apoptosis (Fig. 3A).

To confirm the apoptotic potential of ANXA10, cells that were transfected with ANXA10 were stained with Annexin V/propidium iodide (PI), and compared to the control by flow cytometric analysis. As shown in Fig. 4, the flow cytometry analysis with PI and Annexin V staining, for the dead cells or apoptotic cells, indicated that both early and late stages of apoptosis (M2) were enhanced by introducing ANXA10 into the MKN-1 cells. A significant induction of apoptotic cells was observed in both clones with the ANXA10 expression vector compared to the cells treated with the pcDNA3.1/HisC_Mock vector (none or Mock vector treatment). The apoptotic cells (right in dot-plot graphs of Fig. 4) increased from 40.67% to 50.69% in the pcDNA3.1/HisC_ANXA10-clone1 and pcDNA3.1/HisC_ANXA10-clone3, ANXA10 expression vector groups, compared to no treatment (17.97%) or Mock vector (17.56%) treatment.

Discussion

The ANXs are a multigene family of closely related calcium binding proteins without EF-hands (the helix-loop-helix calcium-binding motif) and charged phospholipids of membrane binding proteins that show type specific expression (23). There are at least 12 human ANX members, designated A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, and A13 (20). The ANXs shares a similar structure that is characterized by the presence of four or eight repeats of a 70-amino acid motif and a highly variable amino terminal end (23-25). Among the more than 13 ANX family members, different ANXs have unique tissue and cell distribution in vertebrates. ANXA2, A5,
A6, and -A11 are ubiquitous, whereas ANXA3, -A8, and -A13 have a more restricted tissue distribution (23,26,27). Some ANXs are overexpressed in several types of cancers, while others show loss of expression.

There is also increasing evidence to indicate that the changes in ANX expression and/or subcellular localization of ANXs contribute to the development and progression of cancer. Several of the ANX genes are located in chromosomal regions that show a high frequency of loss in specific types of cancer, suggesting that these ANXs may be tumor suppressor genes (20,28,29). ANXA10, a member of the ANX family, has several distinct features, including rare expression, codon deletion in conserved repeat 3, and an unusual ablation of the type II calcium binding sites in tetrad core repeats (30).

ANXA10 has been recently considered a potential gene therapy target for hepatocellular carcinoma due to its reduced expression associated with vascular invasion, early recurrence, and poor prognosis associated with the p53 mutation (21); it is located on chromosome 4 at band q33 (31). Chromosome 4q is one of the most common regions associated with a high frequency of allelic loss in hepatocellular carcinoma (32-35). ANXA10, a member of the ANX family, has several distinct features, including rare expression, codon deletion in conserved repeat 3, and an unusual ablation of the type II calcium binding sites in tetrad core repeats (30).

ANXA10 expression has been shown to be reduced in gastric carcinoma based on the findings of previous studies. In addition, large-scale molecular changes in colon cancer have been suggested by expression profiling (37). In the present study, the results showed down-regulation of ANXA10 in gastric carcinomas; in addition, recombinant plasmid-mediated protein overexpression of ANXA10 suppressed the growth properties of MKN-1 cancer cells. The analysis of endogenous expression of ANXA10, in the gastric cancer cell lines, revealed no detectable mRNA, with the exception of SNU-638 and -719 (Fig. 1B).

With regard to the biological activity of ANXA10 during tumor progression, there are several lines of evidence that indicate that ANXA10 acts as an anti-proliferative and anti-survival factor in several types of cancer cells including hepatocellular carcinomas and gastric cancer cells (13,21). The results of this study showed dysregulation of ANXA10 in gastric carcinoma. To determine the biological role of ANXA10 in gastric carcinoma, recombinant plasmid-mediated gene overexpression was employed. The overexpression of endogenous ANXA10 in gastric carcinoma, recombinant plasmid-mediated gene overexpression was employed. The overexpression of endogenous ANXA10, in the MKN-1 cells, resulted in the regression of cell growth (Fig. 3B) and increased the fraction of apoptotic cells (Fig. 4). According to a recent study, silencing of endogenous ANXA10 stimulated the migration rate of cells and increased the number of colonies of the MKN-1 cells, which was then decreased when transfected with expression plasmid cDNA (13). The results of this study
are consistent with previous findings that suggest that ANXA10 might act as a tumor suppressor in gastric cancer cells by restraining cell growth and inducing basal apoptosis.

To estimate the clinical significance of ANXA10 expression, gastric carcinoma specimens were analyzed using an immunostaining method; the results showed that expression of the ANXA10 protein was slightly decreased in 31 out of the 122 gastric carcinomas tested (25.4%), and resulted in negative or weak positive staining with the ANXA10 antibody. However, 20 out of the 122 (16.4%) normal gastric tissues showed negative or weak positive staining (Fig. 2 and Table I). ANXA10 expression was found to be reduced in mucinous adenocarcinoma suggesting that the loss of ANXA10 may reflect the loss of exocytotic function during the dedifferentiation process in gastric carcinogenesis. Low ANXA10 expression was associated with a poor prognosis in patients with HCC and gastric carcinoma (13,21).

In conclusion, the results of this study showed reduced-expression of ANXA10 in both cancer cell lines and human gastric carcinomas. In addition, overexpression of ANXA10 in gastric cancer cell lines suppressed tumor cell growth and induced apoptosis. These results suggest that loss of ANXA10 expression may contribute to tumor cell growth and survival. To confirm these results, additional target proteins and their biological activity must be studied.

Acknowledgements

This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0072504) and by a grant of the Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A084930) and by the Korean Science and Engineering Foundation via the Cell Death Disease Research Center at The Catholic University of Korea.

References